## Abstract Prenatal diagnosis was performed in 81 cases at risk for the fragile X syndrome. There were 12 fra (X)βpositive cases, two of which showed low expression in cultured amniotic fluid cells. FUdR and high thymidine were used for induction of fra(X) (q27.3) expression in all cases. In 21 ca
Prenatal diagnosis and carrier screening for fragile X by PCR
β Scribed by Brown, W. Ted; Nolin, Sarah; Houck, George; Ding, Xiaohua; Glicksman, Anne; Li, Shu-Yun; Stark-Houck, Sandra; Brophy, Patricia; Duncan, Charlotte; Dobkin, Carl; Jenkins, Ed
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 28 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0148-7299
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Objective: The objective of this study was to conduct an economic evaluation of routine prenatal carrier testing for fragile X syndrome. Methods: This economic analysis was conducted from the societal perspective. A cost-benefit equation was developed based on the premise that the cost of routi
We reviewed the distribution of autosomal fragile sites (FS) and spontaneous chromosome breaks or gaps (CB) at chromosome locations other than those recognized as FS from 100 amniotic fluid samples (AF), 19 chorionic villus samples (CVS), and 5 percutaneous umbilical blood samples (PUBS) referred fo
The success of prenatal carrier screening as a disease prevention strategy in the Ashkenazi Jewish (AJ) population has driven the expansion of screening panels as disease-causing founder mutations have been identified. However, the carrier frequencies of many of these mutations have not been reporte
The results of 30 prenatal diagnoses for fragile X syndrome are reported. Amniotic fluid cells were examined in 1 case, fetal blood in 4, and chorionic villi samples in the others. Of the 5 fetuses analyzed by cytogenetic methods, 1 had showed 4% of fraXq27.3 expression sites and the pregnancy was t